Dynavax Technologies (NASDAQ:DVAX) Raised to Buy at StockNews.com

Dynavax Technologies (NASDAQ:DVAX) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Tuesday.

Separately, HC Wainwright boosted their price objective on shares of Dynavax Technologies from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday.

Dynavax Technologies Stock Performance

NASDAQ DVAX remained flat at $12.48 during trading hours on Tuesday. The company had a trading volume of 1,464,350 shares, compared to its average volume of 2,092,156. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market capitalization of $1.64 billion, a P/E ratio of 96.01 and a beta of 1.34. The business’s 50 day moving average price is $12.76 and its 200-day moving average price is $11.65. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $14.41.

Institutional Trading of Dynavax Technologies

Several hedge funds and other institutional investors have recently bought and sold shares of DVAX. GAMMA Investing LLC increased its position in shares of Dynavax Technologies by 55.1% in the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 1,457 shares during the period. Sanctuary Advisors LLC raised its position in shares of Dynavax Technologies by 9.1% in the 3rd quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 1,484 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares during the period. US Bancorp DE boosted its position in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares in the last quarter. Finally, Parkman Healthcare Partners LLC increased its stake in Dynavax Technologies by 1.2% in the third quarter. Parkman Healthcare Partners LLC now owns 219,451 shares of the biopharmaceutical company’s stock valued at $2,445,000 after acquiring an additional 2,629 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.